Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Signal transduction molecules in gliomas of all grades.

Ermoian RP, Kaprealian T, Lamborn KR, Yang X, Jelluma N, Arvold ND, Zeidman R, Berger MS, Stokoe D, Haas-Kogan DA.

J Neurooncol. 2009 Jan;91(1):19-26. doi: 10.1007/s11060-008-9683-5. Epub 2008 Sep 1.

2.

PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.

Mueller S, Phillips J, Onar-Thomas A, Romero E, Zheng S, Wiencke JK, McBride SM, Cowdrey C, Prados MD, Weiss WA, Berger MS, Gupta N, Haas-Kogan DA.

Neuro Oncol. 2012 Sep;14(9):1146-52. doi: 10.1093/neuonc/nos140. Epub 2012 Jun 29.

3.

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.

McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, Zheng S, Lamborn KR, Wiencke JK, Chang SM, Prados MD, Berger MS, Stokoe D, Haas-Kogan DA.

J Neurooncol. 2010 Mar;97(1):33-40. doi: 10.1007/s11060-009-0004-4. Epub 2009 Aug 25.

4.

EGFR signals to mTOR through PKC and independently of Akt in glioma.

Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA.

Sci Signal. 2009 Jan 27;2(55):ra4. doi: 10.1126/scisignal.2000014. Erratum in: Sci Signal. 2009;2(60):er4.

5.

Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

Xu G, Zhang W, Bertram P, Zheng XF, McLeod H.

Int J Oncol. 2004 Apr;24(4):893-900.

PMID:
15010827
6.

PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.

Nakamura JL, Karlsson A, Arvold ND, Gottschalk AR, Pieper RO, Stokoe D, Haas-Kogan DA.

J Neurooncol. 2005 Feb;71(3):215-22.

PMID:
15735908
7.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

8.

mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma.

Annovazzi L, Mellai M, Caldera V, Valente G, Tessitore L, Schiffer D.

Anticancer Res. 2009 Aug;29(8):3087-94.

9.

Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.

Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Góth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB.

Endocr Relat Cancer. 2009 Dec;16(4):1329-38. doi: 10.1677/ERC-09-0101. Epub 2009 Jul 20.

10.

Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.

Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR, Nicholas MK, Stokoe D, Haas-Kogan DA.

Clin Cancer Res. 2002 May;8(5):1100-6.

11.

RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN.

Park S, Zhao D, Hatanpaa KJ, Mickey BE, Saha D, Boothman DA, Story MD, Wong ET, Burma S, Georgescu MM, Rangnekar VM, Chauncey SS, Habib AA.

Cancer Res. 2009 May 15;69(10):4107-11. doi: 10.1158/0008-5472.CAN-09-0474. Epub 2009 May 12.

12.
13.

Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.

Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ.

Am J Pathol. 2006 Dec;169(6):2171-80.

14.

Akt-mTOR signaling is involved in Notch-1-mediated glioma cell survival and proliferation.

Zhao N, Guo Y, Zhang M, Lin L, Zheng Z.

Oncol Rep. 2010 May;23(5):1443-7.

PMID:
20372862
15.

Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.

Korkolopoulou P, Levidou G, El-Habr EA, Piperi C, Adamopoulos C, Samaras V, Boviatsis E, Thymara I, Trigka EA, Sakellariou S, Kavantzas N, Patsouris E, Saetta AA.

Histopathology. 2012 Aug;61(2):293-305. doi: 10.1111/j.1365-2559.2012.04236.x. Epub 2012 Jun 13.

PMID:
22690797
16.

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.

Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6. Epub 2002 Sep 23.

17.

Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.

Nathan CO, Amirghahari N, Abreo F, Rong X, Caldito G, Jones ML, Zhou H, Smith M, Kimberly D, Glass J.

Clin Cancer Res. 2004 Sep 1;10(17):5820-7.

18.

Deregulated expression of the clock genes in gliomas.

Chen Z, Liu P, Li C, Luo Y, Chen I, Liang W, Chen X, Feng Y, Xia H, Wang F.

Technol Cancer Res Treat. 2013 Feb;12(1):91-7. doi: 10.7785/tcrt.2012.500250.

PMID:
22905804
19.

Mechanisms of GOLPH3 associated with the progression of gastric cancer: a preliminary study.

Peng J, Fang Y, Tao Y, Li K, Su T, Nong Y, Xie F, Lai M.

PLoS One. 2014 Oct 6;9(10):e107362. doi: 10.1371/journal.pone.0107362. eCollection 2014.

20.

Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.

Miyazaki M, McCarthy JJ, Esser KA.

FEBS J. 2010 May;277(9):2180-91. doi: 10.1111/j.1742-4658.2010.07635.x.

Items per page

Supplemental Content

Write to the Help Desk